Primary Sclerosing Cholangitis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Primary Sclerosing Cholangitis – Pipeline Review, H2 2017’, provides an overview of the Primary Sclerosing Cholangitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Primary Sclerosing Cholangitis

The report reviews pipeline therapeutics for Primary Sclerosing Cholangitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Primary Sclerosing Cholangitis therapeutics and enlists all their major and minor projects

The report assesses Primary Sclerosing Cholangitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Primary Sclerosing Cholangitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Primary Sclerosing Cholangitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acorda Therapeutics Inc

Albireo Pharma Inc

Allergan Plc

Conatus Pharmaceuticals Inc

Dr. Falk Pharma GmbH

Gilead Sciences Inc

iCo Therapeutics Inc.

Intercept Pharmaceuticals Inc

NGM Biopharmaceuticals Inc

Sancilio & Company Inc

Seres Therapeutics Inc

Shenzhen HighTide Biopharmaceutical Ltd

Shire Plc

Sirnaomics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Primary Sclerosing Cholangitis - Overview

Primary Sclerosing Cholangitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Primary Sclerosing Cholangitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Primary Sclerosing Cholangitis - Companies Involved in Therapeutics Development

Acorda Therapeutics Inc

Albireo Pharma Inc

Allergan Plc

Conatus Pharmaceuticals Inc

Dr. Falk Pharma GmbH

Gilead Sciences Inc

iCo Therapeutics Inc.

Intercept Pharmaceuticals Inc

NGM Biopharmaceuticals Inc

Sancilio & Company Inc

Seres Therapeutics Inc

Shenzhen HighTide Biopharmaceutical Ltd

Shire Plc

Sirnaomics Inc

Primary Sclerosing Cholangitis - Drug Profiles

A-4250 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

berberine ursodeoxycholate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bertilimumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Metabolic and Gastrointestinal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cenicriviroc mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-9674 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTD-1801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDN-7314 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

maralixibat chloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGM-282 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

norursodeoxycholic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

obeticholic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-404 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-435 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Primary Sclerosing Cholangitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STP-705 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

timolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Primary Sclerosing Cholangitis - Dormant Projects

Primary Sclerosing Cholangitis - Discontinued Products

Primary Sclerosing Cholangitis - Product Development Milestones

Featured News & Press Releases

Jun 26, 2017: FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC

May 19, 2017: Intercept Receives Innovation Award from the National Organization for Rare Disorders for the Development of Ocaliva (obeticholic acid)

Mar 02, 2017: NICE Recommends Ocaliva (obeticholic acid) for the Treatment of Patients with Primary Biliary Cholangitis in England, Wales and Northern Ireland

Jan 05, 2017: Phenex Receives $100 Million Milestone Payment From Gilead

Aug 26, 2016: Biotie: BTT1023 Receives Orphan Drug Designation in the United States

Jun 07, 2016: Immune Pharmaceuticals and Hadasit File a Joint Patent on the Oral Use of Anti-Eotaxin Monoclonal Antibodies, Including Bertilimumab, for the Treatment of GI and Liver Diseases

Apr 16, 2016: Investigational treatment provides hope for some chronic liver disease sufferers

Jan 07, 2016: Tobira Therapeutics Announces Initiation of Program to Evaluate Cenicriviroc for the Treatment of Primary Sclerosing Cholangitis

Nov 09, 2015: NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD's The Liver Meeting 2015

Nov 03, 2015: Intercept Announces Data to be Presented at the 2015 AASLD Annual Meeting

Mar 31, 2015: Biotie announces start of patient enrolment into Phase 2a clinical study with BTT1023 in primary sclerosing cholangitis

Feb 17, 2015: BTT1023 receives positive opinion for Orphan Drug Designation from COMP

Jul 24, 2014: Clinical study with Biotie's BTT1023 in primary sclerosing cholangitis awarded external grant funding

Nov 18, 2013: Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases

Sep 26, 2013: Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Primary Sclerosing Cholangitis, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Primary Sclerosing Cholangitis – Pipeline by Acorda Therapeutics Inc, H2 2017

Primary Sclerosing Cholangitis – Pipeline by Albireo Pharma Inc, H2 2017

Primary Sclerosing Cholangitis – Pipeline by Allergan Plc, H2 2017

Primary Sclerosing Cholangitis – Pipeline by Conatus Pharmaceuticals Inc, H2 2017

Primary Sclerosing Cholangitis – Pipeline by Dr. Falk Pharma GmbH, H2 2017

Primary Sclerosing Cholangitis – Pipeline by Gilead Sciences Inc, H2 2017

Primary Sclerosing Cholangitis – Pipeline by iCo Therapeutics Inc., H2 2017

Primary Sclerosing Cholangitis – Pipeline by Intercept Pharmaceuticals Inc, H2 2017

Primary Sclerosing Cholangitis – Pipeline by NGM Biopharmaceuticals Inc, H2 2017

Primary Sclerosing Cholangitis – Pipeline by Sancilio & Company Inc, H2 2017

Primary Sclerosing Cholangitis – Pipeline by Seres Therapeutics Inc, H2 2017

Primary Sclerosing Cholangitis – Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H2 2017

Primary Sclerosing Cholangitis – Pipeline by Shire Plc, H2 2017

Primary Sclerosing Cholangitis – Pipeline by Sirnaomics Inc, H2 2017

Primary Sclerosing Cholangitis – Dormant Projects, H2 2017

Primary Sclerosing Cholangitis – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Primary Sclerosing Cholangitis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports